Key TakeawaysRegulatory submission for retatrutide now expected in Q1 2027, pushed back from the initial 2025 timelinePhase 3 data showed patients with obesity and Type 2 diabetes experienced average weight reduction of 20.8% (approximately 50 pounds) over 80 weeksThose with obesity and cardiovascular conditions saw 22.6% average body weight loss (around 55.8 pounds) at the 80-week markThe drug activates three distinct hormonal pathways (GLP-1, GIP, glucagon), exceeding the mechanism of competing therapiesTD Cowen projects potential annual revenue of $3.8 billion for retatrutide by 2030Eli Lilly revealed on Thursday its intention to seek regulatory clearance for retatrutide, its advanced obesity treatment candidate, during the opening quarter of 2027. This represents a shift from the pharmaceutical giant’s previous goal of 2025. Shares of LLY advanced 1.99% during Thursday’s trading session.Eli Lilly and Company, LLYAccording to the company, additional time is necessary to compile and validate manufacturing processes and quality assurance documentation demanded by health authorities.Administered as a once-weekly injection, retatrutide successfully completed two separate Phase 3 clinical studies, delivering weight reduction outcomes that surpass currently available medications.The first study demonstrated that participants living with obesity and Type 2 diabetes achieved a mean body weight reduction of 20.8% — roughly 50 pounds — across an 80-week treatment period.A companion study revealed that individuals with severe obesity and pre-existing cardiovascular conditions experienced a mean weight decrease of 22.6%, equating to approximately 55.8 pounds, during the identical timeframe.Retatrutide’s Unique Mechanism of ActionRetatrutide distinguishes itself through its innovative mechanism. The medication activates three separate hormonal pathways: GLP-1, GIP, and glucagon receptors.By comparison, Lilly’s existing bestseller Zepbound engages GLP-1 and GIP receptors. Novo Nordisk’s Wegovy activates only the GLP-1 pathway. Retatrutide’s triple-receptor strategy represents uncharted territory in obesity pharmacotherapy.Adverse events documented during clinical testing included diarrhea, nausea, and constipation — side effects that align with other medications in the GLP-1 receptor agonist category.Kenneth Custer, who leads Lilly’s Cardiometabolic Health division, expressed confidence that the company possesses sufficient data for worldwide regulatory submissions, addressing not only obesity but additional conditions including knee osteoarthritis pain management and obstructive sleep apnea.Wall Street Projections and Market SentimentIn January, TD Cowen analysts forecasted that retatrutide could achieve $3.8 billion in annual revenue by 2030. This would position it as a cornerstone asset within Lilly’s obesity treatment lineup, complementing Zepbound and the recently introduced oral formulation, Foundayo.The development of retatrutide represents Lilly’s strategic effort to maintain competitive advantage over Novo Nordisk in the expanding worldwide weight-management pharmaceutical sector.Current analyst consensus from 22 Wall Street firms covering LLY indicates a Strong Buy rating. This assessment reflects 20 Buy recommendations and two Hold ratings published within the last three months.The mean price target for LLY stands at $1,294.06, suggesting potential upside of approximately 17% from present trading levels.The post Eli Lilly (LLY) Stock Climbs 2% on Retatrutide Weight-Loss Drug Data appeared first on Blockonomi.